- Presentation of five scientific abstracts selected for poster
presentations at the AASLD The Liver Meeting™ 2021 by Prof. Nezam
Afdhal and Prof. Jörn Schattenberg
- Update on the current NASH landscape by Prof. Nezam Afdhal
- Update on Inventiva’s Phase II clinical trial evaluating
lanifibranor in patients with type 2 diabetes (T2D) and non
alcoholic fatty liver disease (NAFLD) by Prof. Kenneth Cusi
- Presentation of Inventiva’s Phase IIa combination study with
lanifibranor and SGLT2 inhibitor empagliflozin in patients with
non-cirrhotic NASH and T2D by Prof. Michelle Lai
- Virtual webcast event on November 19, 2021 at 10:30 am (ET) /
4:30 pm (CET)
Daix (France), Long Island City (New
York, United States), November 3, 2021 – Inventiva
(Euronext Paris and Nasdaq: IVA), a clinical-stage
biopharmaceutical company focused on the development of oral small
molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other
diseases with significant unmet medical needs, today announced that
it will host a webcast event focused on NASH with the participation
of four Key Opinion Leaders (KOLs) on November 19, 2021 from The
Liver Meeting™ 2021, organized by the American Association for the
Study of Liver Diseases (AASLD).
Following an introduction from Frédéric
Cren, Chairman, CEO and cofounder of Inventiva and Pierre Broqua,
Chief Scientific Officer and cofounder of Inventiva, the event will
consist of the presentation of five scientific abstracts presented
at AASLD The Liver Meeting™ 2021, as well as four presentations
focused on the latest news around the development of lanifibranor
and various aspects related to NASH. As part of the program, there
will be dedicated Q&A sessions.
The Agenda will be as follows:
Corporate update Speakers: Frederic Cren, CEO
and cofounder of Inventiva Pharma and Pierre Broqua, Chief
Scientific Officer and cofounder of Inventiva Pharma
Update on Inventiva’s NATIV3 Phase III clinical trial in
NASHSpeaker: Dr. Michael Cooreman, Chief Medical Officer
of Inventiva Pharma
Update on the NASH fieldSpeaker: Prof. Nezam
Afdhal, Harvard Medical School in Boston, Massachusetts and Chief
of Hepatology and Director of the Liver Center at Beth Israel
Deaconess Medical Center
Overview of the scientific abstracts presented during
the AASLD Liver MeetingAbstract #1: “Lanifibranor
treatment improves hepatic steatosis in patients with NASH,
evaluated by histological grading and Controlled Attenuation
Parameter (CAP)."Speaker: Prof. Nezam Afdhal, Harvard Medical
School in Boston, Massachusetts and Chief of Hepatology and
Director of the Liver Center at Beth Israel Deaconess Medical
Center
Abstract #2: “Lanifibranor reverses fasting glucose levels to
normoglycemia in prediabetic patients with nonalcoholic
steatohepatitis (NASH)."Speaker: Prof. Nezam Afdhal, Harvard
Medical School in Boston, Massachusetts and Chief of Hepatology and
Director of the Liver Center at Beth Israel Deaconess Medical
Center
Abstract #3: “Liver sinusoidal endothelial cell (LSEC)
capillarization in NASH and its evolution following lanifibranor
treatment: an exploratory study of the NATIVE clinical
trial."Speaker: Prof. Jorn Schattenberg, Director of the Metabolic
Liver Research Program at the University Medical Center of Mainz,
Germany
Abstract #4: "Treatment response to the PAN-PPAR agonist
lanifibranor in the NATIVE study: NASH resolution and fibrosis
improvement are correlated."Speaker: Prof. Jorn Schattenberg,
Director of the Metabolic Liver Research Program at the University
Medical Center Mainz, Germany
Abstract #5: “Lanifibranor improves NASH, fibrosis and diastolic
dysfunction in a hamster preclinical model of diet-induced
NASH.”Speaker: Prof. Jorn Schattenberg, Director of the Metabolic
Liver Research Program at the University Medical Center of Mainz,
Germany
Update on Phase II clinical trial evaluating
lanifibranor in patients with T2DM and NAFLDSpeaker: Prof.
Kenneth Cusi, Chief of the Division of Endocrinology, Diabetes
& Metabolism, University of Florida
Presentation of Phase IIa combination
study with lanifibranor and SGLT2 inhibitor empaglifozin in
patients with NASH and T2DMSpeaker: Prof. Michelle Lai,
Associate Professor of Medicine, Harvard Medical School in Boston,
Massachusetts and Director of NAFLD Center at Beth Israel Deaconess
Medical Center
The details to connect to the webcast are as follows:
Date: |
Friday, November
19, 2021 |
Time: |
10:30 am - 12:30
pm (ET) / 4:30 pm - 6:30 pm (CET) |
Connection details: |
Option #1 –
Webcast: https://edge.media-server.com/mmc/p/cazp5n7z Option
#2 – Conference call: France: +33 (0) 1 70 70 07 81Belgium:
+32 (0) 2 793 3847Germany: +49 (0) 69 2222 2625Netherlands: +31 (0)
20 795 6614Switzerland: +41 (0) 44 580 7145United Kingdom: +44 (0)
207 192 8338United States: +1 646-741-3167 Access code:
2391734 |
The presentation document and the link to the
webcast (live and replay) will also be available on Inventiva’s
website in the “Investors – Investor Presentations” section:
http://inventivapharma.com/investors/investor-presentations/.
•••
About the American Association for the Study of Liver
Diseases (AASLD)1
AASLD is the leading organization of scientists
and health care professionals committed to preventing and curing
liver disease. AASLD fosters research that leads to improved
treatment options for millions of liver disease patients. We
advance the science and practice of hepatology through educational
conferences, training programs, professional publications, and
partnerships with government agencies and sister societies.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH, MPS and other diseases with significant
unmet medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
two clinical candidates, as well as a deep pipeline of earlier
stage programs.
Lanifibranor, its lead product candidate, is
being developed for the treatment of patients with NASH, a common
and progressive chronic liver disease for which there are currently
no approved therapies. Inventiva recently announced positive
topline data from its Phase IIb clinical trial evaluating
lanifibranor for the treatment of patients with NASH and obtained
Breakthrough Therapy and Fast Track designation for lanifibranor in
the treatment of NASH. Lanifibranor is currently being evaluated in
a pivotal Phase III clinical trial.
Inventiva is also developing odiparcil, a second
clinical stage asset, for the treatment of patients with subtypes
of MPS, a group of rare genetic disorders. Inventiva announced
positive topline data from its Phase IIa clinical trial evaluating
odiparcil for the treatment of adult MPS VI patients at the end of
2019 and received FDA Fast Track designation in MPS VI for
odiparcil in October 2020.
In parallel, Inventiva is in the process of
selecting an oncology development candidate for its Hippo
signalling pathway program. Furthermore, the Company has
established a strategic collaboration with AbbVie in the area of
autoimmune diseases. AbbVie has started the clinical development of
ABBV‑157, a drug candidate for the treatment of moderate to severe
psoriasis resulting from its collaboration with Inventiva. This
collaboration enables Inventiva to receive milestone payments upon
the achievement of pre-clinical, clinical, regulatory and
commercial milestones, in addition to royalties on any approved
products resulting from the collaboration.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
InventivaPascaline ClercVP of Global External
Affairs media@inventivapharma.com+1 240 620 9175 |
Brunswick GroupLaurence Frost / Tristan Roquet
Montegon / Aude LepreuxMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke,
an ICR CompanyPatricia L. Bank Investor
relationspatti.bank@westwicke.com+1 415 513 1284 |
|
|
|
Important Notice
This press release contains forward-looking
statements, forecasts and estimates with respect to Inventiva’s
clinical trials, clinical trial data releases, clinical development
plans and anticipated future activities of Inventiva. Certain of
these statements, forecasts and estimates can be recognized by the
use of words such as, without limitation, “believes”,
“anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”,
“may”, “will” and “continue” and similar expressions. Such
statements are not historical facts but rather are statements of
future expectations and other forward-looking statements that are
based on management's beliefs. These statements reflect such views
and assumptions prevailing as of the date of the statements and
involve known and unknown risks and uncertainties that could cause
future results, performance or future events to differ materially
from those expressed or implied in such statements. Actual events
are difficult to predict and may depend upon factors that are
beyond Inventiva's control. There can be no guarantees with respect
to pipeline product candidates that the clinical trial results will
be available on their anticipated timeline, with respect to the
anticipated timeline for seeking of regulatory approvals for
candidates, or that candidates will receive the necessary
regulatory approvals. Actual results may turn out to be materially
different from the anticipated future results, performance or
achievements expressed or implied by such statements, forecasts and
estimates, due to a number of factors, including that Inventiva is
a clinical-stage company with no approved products and no
historical product revenues, Inventiva has incurred significant
losses since inception, Inventiva has a limited operating history
and has never generated any revenue from product sales, Inventiva
will require additional capital to finance its operations,
Inventiva's future success is dependent on the successful clinical
development, regulatory approval and subsequent commercialization
of current and any future product candidates, preclinical studies
or earlier clinical trials are not necessarily predictive of future
results and the results of Inventiva's clinical trials may not
support Inventiva's product candidate claims, Inventiva may
encounter substantial delays in its clinical trials or Inventiva
may fail to demonstrate safety and efficacy to the satisfaction of
applicable regulatory authorities, enrollment and retention of
patients in clinical trials is an expensive and time-consuming
process and could be made more difficult or rendered impossible by
multiple factors outside Inventiva's control, Inventiva's product
candidates may cause adverse drug reactions or have other
properties that could delay or prevent their regulatory approval,
or limit their commercial potential, Inventiva faces substantial
competition and Inventiva’s business, and preclinical studies and
clinical development programs and timelines, its financial
condition and results of operations could be materially and
adversely affected by the current COVID-19 pandemic. Given these
risks and uncertainties, no representations are made as to the
accuracy or fairness of such forward-looking statements, forecasts
and estimates. Furthermore, forward-looking statements, forecasts
and estimates only speak as of the date of this press release.
Readers are cautioned not to place undue reliance on any of these
forward-looking statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2020 filed with the
Autorité des Marchés Financiers on March 15, 2021, the Annual
Report on Form 20-F for the year ended December 31, 2020 filed with
the Securities and Exchange Commission on March 15, 202, Amendment
No. 1 to our Annual Report on Form 20-F for the year ended December
31, 2020 filed with the Securities and Exchange Commission on March
24, 2021, as well as the full-year financial report for the year
ended December 31, 2020 for additional information in relation to
such factors, risks and uncertainties.
Except as required by law, Inventiva has no
intention and is under no obligation to update or review the
forward-looking statements referred to above. Consequently,
Inventiva accepts no liability for any consequences arising from
the use of any of the above statements.
1 https://www.aasld.org/
- Inventiva - PR - AASLD KOL - EN - 03 11 2021
Inventiva (EU:IVA)
Historical Stock Chart
From May 2024 to Jun 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Jun 2023 to Jun 2024